Table 3.
Antibiotic Resistant Pattern of Isolated Bacterial Isolates Against Various Antibiotics
| Bacteria Antibiotics |
Acinetobacter baumannii (35) | Klebsiella pneumoniae (39) | Pseudomonas aeruginosa (25) | Proteus spp. (23) | Providencia stuartii (12) | Escherichia coli (10) | MRSA (6) | Enterobacter spp. (5) | Serratia marcescens (3) | Overall Isolates |
|---|---|---|---|---|---|---|---|---|---|---|
| Amikacin | 30 (85.7%) | 31 (79.5%) | 7 (28%) | 10 (43.5%) | 5 (41.7%) | 1 (10%) | – | 2 (40%) | – | 86/149 (57.7%) |
| Amoxicillin/ clavulanic acid | 35 (100%) | 35 (89.7%) | 21 (84%) | 20 (87.0%) | 12 (100%) | 6 (60%) | 5 (83.3%) | 5 (100%) | 3 (100%) | 142/158 (89.9%) |
| Ampicillin | 30 (85.7%) | 36 (92.3%) | 19 (76%) | 23 (100%) | 12 (100%) | 8 (80%) | 3 (50%) | 5 (100%) | 3 (100%) | 139/158 (88%) |
| Aztreonam | 31 (88.6%) | 34 (87.2%) | 15 (60%) | 15 (65.2%) | 10 (83.3%) | 8 (80%) | – | 5 (100%) | 1 (33.3%) | 119/152 (78.3%) |
| Cefepime | 34 (97.1%) | 32 (82.1%) | 15 (60%) | 20 (87.0%) | 9 (75.0%) | 6 (60%) | – | 4 (80%) | 1 (33.3%) | 121/152 (79.6%) |
| Cefoxitin | 32 (91.4%) | 23 (59.0%) | 17 (68%) | 11 (47.8%) | 2 (16.7%) | 5 (50%) | 5 (83.3%) | 3 (60%) | 1 (33.3%) | 99/158 (62.7%) |
| Ceftazidime | 34 (97.1%) | 28 (71.8%) | 20 (80%) | 21 (91.3%) | 11 (91.7%) | 7 (70%) | – | 2 (40%) | 1 (33.3%) | 124/152 (81.6%) |
| Ceftriaxone | 33 (94.3%) | 31 (79.5%) | 19 (76%) | 20 (87.0%) | 8 (66.7%) | 6 (60%) | – | 4 (80%) | 1 (33.3%) | 122/152 (80.3%) |
| Cefuroxime | 31 (88.6%) | 30 (76.9%) | 21 (84%) | 21 (91.3%) | 12 (100%) | 7 (70%) | 1 (16.7%) | 5 (100%) | 3 (100%) | 131/158 (82.9%) |
| Cephalothin | 29 (82.9%) | 33 (84.6%) | 21 (84%) | 22 (95.7%) | 11 (91.7%) | 8 (80%) | – | 5 (100%) | 3 (100%) | 132/152 (86.8%) |
| Ciprofloxacin | 35 (100%) | 35 (89.7%) | 16 (64%) | 22 (95.7%) | 6 (50%) | 9 (90%) | – | 5 (100%) | 1 (33.3%) | 129/152 (84.9%) |
| Colistin | – | 16 (41.0%) | 7 (28%) | 18 (78.3%) | 8 (66.7%) | – | – | 1 (20%) | 2 (66.7%) | 52/107 (48.6%) |
| Ertapenem | 31 (88.6%) | 32 (82.1%) | 20 (80%) | 8 (34.8%) | 5 (41.7%) | 4 (40%) | – | 5 (100%) | 1 (33.3%) | 106/152 (69.7%) |
| Gentamycin | 28 (80.0%) | 19 (48.7%) | 14 (56%) | 19 (82.6%) | 12 (100%) | 4 (40%) | 5 (83.3%) | 2 (40%) | 1 (33.3%) | 104/158 (65.8%) |
| Imipenem | 31 (88.6%) | 22 (56.4%) | 11 (44%) | 4 (17.4%) | 2 (16.7%) | 2 (20%) | 5 (83.3%) | 3 (60%) | – | 80/155 (51.6%) |
| Levofloxacin | 32 (91.4%) | 36 (92.3%) | 15 (60%) | 21 (91.3%) | 12 (100%) | 7 (70%) | – | 4 (80%) | – | 127/149 (85.2%) |
| Meropenem | 35 (100%) | 25 (64.1%) | 10 (40%) | 7 (30.4%) | 3 (25.0%) | 3 (30%) | – | 1 (20%) | – | 84/149 (56.4%) |
| Nitrofurantoin | 34 (97.1%) | 25 (64.1%) | 20 (80%) | 20 (87.0%) | 12 (100%) | 6 (60%) | – | 5 (100%) | 3 (100%) | 125/152 (82.2%) |
| Oxacillin | – | – | – | – | – | – | 6 (100%) | – | – | 6/6 (100%) |
| Piperacillin / Tazobactam | 26 (74.3%) | 19 (48.7%) | 10 (40%) | 3 (13.0%) | 3 (25.0%) | 5 (50%) | – | 1 (20%) | – | 67/149 (45%) |
| Tigecycline | 21 (60%) | – | 1 (4%) | 2 (8.7%) | – | – | – | – | – | 24/83 (28.9%) |
Abbreviation: MRSA, Methicillin-resistant Staphylococcus aureus.